Actively Recruiting
Evaluating the Efficacy and Safety of AXS-14 Esreboxetine Compared to Placebo in Adults with Fibromyalgia Using a Randomized Withdrawal Design
Led by Axsome Therapeutics, Inc. · Updated on 2026-09-04
620
Participants Needed
53
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating AXS-14 esreboxetine for managing fibromyalgia in a Phase 3, double-blind, placebo-controlled, randomized withdrawal study. The study aims to assess the efficacy and safety of AXS-14 for people diagnosed with fibromyalgia based on the 2016 ACR diagnostic criteria. The trial includes a multi-center design with two main periods. First, participants receive open-label AXS-14 tablets once daily for up to 12 weeks. Those who respond to treatment are then randomized to either continue AXS-14 or switch to placebo for an additional 12 weeks or until loss of therapeutic response occurs. Participants will be involved for up to 24 weeks in total. During this time, they will take study tablets daily and undergo assessments to monitor their response and safety. The primary outcome measured is the time from randomization to loss of therapeutic response over 12 weeks. Safety and efficacy are closely monitored throughout the study.
CONDITIONS
Brief Title
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here